Efficacy and compliance of montelukast as prophylaxis in mild persistent asthma
DOI:
https://doi.org/10.18203/2349-3291.ijcp20184201Keywords:
Allergic rhinitis, Childhood asthma, Leukotriene antagonist, Montelukast, PhenotypeAbstract
Background: Bronchial Asthma is characterized by hyperresponsiveness of airways to various triggers. The management goals of asthma therapy are to control asthma so that the affected child can lead a normal life without asthma exacerbations. In spite of several advances in the management aspects, asthma morbidity remains the same. Under diagnosis, inappropriate therapy and poor compliance are the major contributors to asthma morbidity. In the recent years the knowledge about different clinical and biological phenotypes of asthma has helped in deciding the treatment options in bronchial asthma. Montelukast has proven to be particularly effective in exercise induced asthma and asthma associated with allergic rhinitis. The aim of this study is to assess the efficacy and compliance of montelukast for prophylaxis in mild persistent asthma in children aged 1-12 years.
Methods: This is a prospective study which included children between age group 1-12 years with mild persistent asthma who was started on montelukast during the 12-month period from September 2016 to October 2017. No. of children who were controlled with moutelukast and who needed step up treatment were noted. Comorbidities of children who were controlled on montelukast were also studied.
Results: At the end of 6 months, 86.4% of children were well controlled and 13.6% were not well controlled.91.5% who were well controlled belonged to 1-5 years age group. Children with comorbidities like allergic rhinitis had good control with moutelukast. Response to montelukast was good when viral infection was a trigger.
Conclusions: It is a safe drug with modest benefits in bronchial asthma. It is useful in mild persistent asthma where ICS administration is impractical and also in patients with comorbidities like allergic rhinitis. It is also found to decrease the episode of viral induced wheeze in young children.
References
Paggiaro P, Bacci E. Montelukast in asthma: a review of its efficacy and place in therapy. Therapeutic Advances Chronic Dise. 2011;2(1):47-58.
Holgate ST, Peters-Golden M, Panettieri RA, Henderson Jr WR. Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling. J Allergy Clin Immunol. 2003;111(1):S18-36.
Hamid Q, Tulic MK, Liu MC, Moqbel R. Inflammatory cells in asthma: mechanisms and implications for therapy. J Allergy Clin Immunol. 2003;111(1):S5-17.
Asakura T, Ishii Y, Chibana K, Fukuda T. Leukotriene D4 stimulates collagen production from myofibroblasts transformed by TGF-β. J Allergy Clin Immunol. 2004;114(2):310-5.
Altraja S, Kadai M, Rekker E, Altraja A. Synthesis of tenascin and laminin beta2 chain in human bronchial epithelial cells is enhanced by cysteinyl leukotrienes via CysLT 1 receptor. Respiratory Research. 2008;9(1):44.
Walia M, Lodha R, Kabra SK. Montelukast in pediatric asthma management. Indian J Pediatr. 2006;73(4):275-82.
Global Initiative for Asthma. Global strategy for asthma management and prevention. 2007. Aavailable at www.ginasthma.org
Bisgaard H, Zielen S, Garcia-Garcia ML. Montelukast reduces asthma exacerbations in 2 to 5-year-old children with intermittent asthma. Am J Respir Crit Care Med. 2005;171:315-22.
Stelmach I, Bobrowska-Korzeniowska M, Majak P, Stelmach W, Kuna P. The effect of montelukast and different doses of budesonide on IgE serum levels and clinical parameters in children with newly diagnosed asthma. Pulmonary Pharmacol Therapeutics. 2005;18(5):374-80.
Szefler SJ, Phillips BR, Martinez FD, Chinchilli VM, Lemanske Jr RF, Strunk RC, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol. 2005;115(2):233-42.
Garcia ML, Wahn U, Gilles L, Swern A, Tozzi CA, Polos P. Montelukast compared with fluticasone, control of asthma among 6 to 14-year-old patients with mild asthma: The MOSAIC study. Pediatr. 2005;116:360-9.
Karamana Ö, Sünneli L, Uzuner N, Işlekel H, Turgut CS, Köse S, et al. Evaluation of montelukast in 8 to 14-year-old children with mild persistent asthma and compared with inhaled corticosteroids. Allergologia et immunopathologia. 2004;32(1):21-7.
Bukstein DA, Luskin AT, Bernstein A. Real world effectiveness of daily controller medicine in children with mild persistent asthma. Ann Allergy Asthma Immunol. 2003;90:543-9.
Doherty GM. Is montelukast effective and well tolerated in the management of asthma in young children? Part A: Evidence-based answer and summary. Paediatr Child Health. 2007;12(4):307-8.
Melo RE, Sole D, Naspitz CK. Exercise-induced bronchoconstriction in children: montelukast attenuates the immediate phase and late phase responses. J Allergy Clin Immunol. 2003;111:301-17.
Pajaron‐Fernandez M, Garcia‐Rubia S, Sanchez‐Solis M, Garcia‐Marcos L. Montelukast administered in the morning or evening to prevent exercise‐induced bronchoconstriction in children. Pediatric Pulmonol. 2006;41(3):222-7.
Kupczyk M, Kupryś I, Gorski P, Kuna P. The effect of montelukast (10 mg daily) and loratadine (10 mg daily) on wheal, flare and itching reactions in skin prick tests. Pulmonary Pharmacol Therapeutics. 2007;20(1):85-9.
Mucha SM, Naclerio RM, Baroody FM. Comparison of montelukast and pseudoephedrine in the treatment of allergic rhinitis. Arch Otolaryngol–Head Neck Surg. 2006;132(2):164-72.
Jartti T. Inhaled corticosteroids or montelukast as the preferred primary long-term treatment for pediatric asthma? Eu J Pediatr. 2008;167(7):731-6.
Knorr B, Franchi LM, Bisgaard H, Vermeulen JH, LeSouef P, Santanello N, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatr. 2001;108(3):e48.
